Illumina has appointed Jonathan Seaton as senior VP for corporate and business development. In this role, Seaton will be responsible for global business development activities, including strategic commercial deals, mergers and acquisitions, licensing, and partnerships. He joins Illumina from Becton Dickinson, where he was VP and head of strategy and business development for the Life Sciences segment. He previously held leadership roles at Hoffman-La Roche, Roche Tissue Diagnostics, LS9, and several consulting firms and investment banks.
Clinical Genomics has appointed Mark Boyle as president of in vitro diagnostics. Boyle joins Clinical Genomics from Qiagen, where he served as a VP for nearly five years. Previously, he served as president of Cellestis, prior to that firm's acquisition by Qiagen and successful integration into the company. He has also served as general manager for the UK subsidiary of Diagnostics Systems Laboratories.
Portable Genomics has appointed Aarush Manchanda to its board of directors. Manchanda is board certified in internal medicine, cardiovascular disease, nuclear cardiology, cardiac computed tomography, and echocardiography. He currently works as a staff cardiologist at Cedar City Heart Clinic in Cedar City, Utah. He also serves as medical director of Cardiovascular Services at Cedar City Hospital.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.